Primary Central Nervous System Lymphoma Clinical Trials in Boston, Massachusetts
5 recruitingBoston, Massachusetts
Showing 1–5 of 5 trials
Recruiting
Phase 3
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Relapsed/Refractory Primary Central Nervous System Lymphoma
Ono Pharmaceutical Co., Ltd.132 enrolled8 locationsNCT07104032
Recruiting
Phase 1Phase 2
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078
Recruiting
Phase 1
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
LymphomaPrimary Central Nervous System Lymphoma
Dana-Farber Cancer Institute15 enrolled2 locationsNCT06475235
Recruiting
Phase 1Phase 2
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Refractory CancerPrimary Central Nervous System LymphomaRecurrent Cancer+1 more
Dana-Farber Cancer Institute37 enrolled4 locationsNCT04421560
Recruiting
Phase 2
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
Primary Central Nervous System LymphomaNon-Hodgkin Lymphoma of Extranodal Site
Lakshmi Nayak, MD25 enrolled2 locationsNCT04906096